Læknablaðið - 15.02.2010, Page 6

EINUNGIS Cervarix
i veitir vörn gegn fimm
L algengustu krabbameins-
valdandi HPV-veirum*:
K 16, 18,31,33 og45
Virkni bóluefnisns er bre/tileg fyrir hverja
HPV-veirutegund 16, 18,31,33.45 og er
mismunandi milli hópa og endapunkta
Heimildir:
1. Paavonen J, Naud P Salmerón J, etal. Efficacy of human
papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine
against cervical infection and precancer caused by
oncogenic HPV types (PATRICIA): final analysis of a
double blind, randomised study in young women.
Lancet 2009; 374: 301-14.
2. Bosch FX, Burchell AN, Shiffman M, et al.
Epidemiology and Natural History of Human
Papilomavirus Infections andType-Specific Implications
in Cervical Neoplasia.Vaccine 2008; 26S: Kl -Kl 6.
3. European Summary of Product Characteristics.
Gardasil®. Sanofi Pasteur MSD, 2009.
Cervarix
Bóluefni gegn mannapapillomaveirum, gerðum 16 og 18
(raðbrigði, ónæmisglætt, aðsogað) sériyfjatexti á bis. 141